BLINCYTO
Clinical safety rating
cautionComprehensive clinical and safety monograph for BLINCYTO (BLINCYTO).
Comprehensive clinical and safety monograph for BLINCYTO (BLINCYTO).
Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) in adults and childrenB-cell precursor ALL in first or second complete remission with minimal residual disease (MRD) ≥0.1% in adults and children
Bispecific CD19-directed CD3 T-cell engager; binds CD19 on B cells and CD3 on T cells, activating endogenous T cells to lyse CD19-expressing B cells.
| Metabolism | Metabolized to small peptides by catabolic pathways; not metabolized by CYP enzymes. |
| Excretion | Blinatumomab is not metabolized by cytochrome P450 enzymes; it is expected to be degraded into small peptides and amino acids via catabolic pathways. No specific excretion studies have been conducted; however, clearance is primarily through non-specific proteolysis, and no significant renal or biliary excretion of intact drug occurs. The contribution of renal elimination to total clearance is minimal (<1%). |
| Half-life | The terminal elimination half-life of blinatumomab is approximately 2.11 hours (range 1.2–2.5 hours) during continuous intravenous infusion. The short half-life necessitates continuous infusion to maintain therapeutic concentrations. |
| Protein binding | Blinatumomab is a monoclonal antibody; protein binding is negligible at clinically relevant concentrations. No specific binding to plasma proteins has been reported. |
| Volume of Distribution | The volume of distribution (Vd) at steady state is approximately 3.13 L (range 2.35–4.38 L), corresponding to about 0.04 L/kg (assuming 70 kg body weight), suggesting limited extravascular distribution consistent with a large monoclonal antibody. |
| Bioavailability | Blinatumomab is administered as a continuous intravenous infusion; bioavailability by this route is 100%. No other routes are clinically relevant. |
| Onset of Action | Clinical response (e.g., reduction in bone marrow blasts) can be observed within 2 to 4 weeks after initiation of continuous intravenous infusion at the recommended dosing regimen. |
| Duration of Action | The duration of action is dependent on continuous infusion; pharmacodynamic effects (e.g., T-cell activation and cytokine release) persist for the duration of the infusion. After infusion discontinuation, drug concentrations decline rapidly due to short half-life, and clinical effects wane accordingly. |
| Molecular Weight | 55000 |
Continuous intravenous infusion over 28 days per cycle. For patients ≥45 kg: 9 mcg/day on days 1-7 and 28 mcg/day on days 8-28 for cycle 1, then 28 mcg/day on days 1-28 for subsequent cycles. For patients <45 kg: 5 mcg/m2/day on days 1-7 and 15 mcg/m2/day on days 8-28 for cycle 1, then 15 mcg/m2/day on days 1-28 for subsequent cycles. Hospitalization recommended for first 9 days of cycle 1 and first 2 days of subsequent cycles.
| Dosage form | INJECTABLE |
| Renal impairment | No dose adjustment recommended for mild to moderate renal impairment (CrCl ≥30 mL/min). For severe renal impairment (CrCl <30 mL/min) or dialysis, use with caution and monitor for increased toxicity; specific dose adjustments not established. |
| Liver impairment | No dedicated Child-Pugh based adjustments available. Use with caution in patients with moderate to severe hepatic impairment; monitor for hepatotoxicity. |
| Pediatric use | For patients weighing ≥45 kg: same as adult dosing. For patients <45 kg: based on body surface area (BSA). Cycle 1: 5 mcg/m2/day (max 9 mcg/day) on days 1-7, then 15 mcg/m2/day (max 28 mcg/day) on days 8-28. Subsequent cycles: 15 mcg/m2/day (max 28 mcg/day) on days 1-28. Administer as continuous IV infusion over 28 days. |
| Geriatric use | No specific dose adjustment recommended for elderly patients. Monitor closely for adverse reactions, particularly neurologic events and infections, as clinical studies included limited patients aged ≥65 years. |
| 1st trimester | There are no adequate and well-controlled studies in pregnant women. Based on its mechanism of action (CD19-directed cytolytic activity), blinatumomab may cause fetal harm when administered to a pregnant woman. Human IgG antibodies are known to cross the placenta; however, blinatumomab is a bispecific T-cell engager (BiTE) antibody construct with a short half-life. Animal reproduction studies have not been conducted. Use only if potential benefit justifies potential risk to the fetus. |
| 2nd trimester | Same as first trimester. Potential risks include fetal B-cell depletion and immunological abnormalities. Clinical monitoring is recommended if exposure occurs. |
| 3rd trimester | Same as first and second trimesters. Near term, there is increased transfer of IgGs across placenta; however, blinatumomab is not a full IgG. Limited data available. |
Clinical note
Comprehensive clinical and safety monograph for BLINCYTO (BLINCYTO).
| Placental transfer | Blinatumomab is a bispecific T-cell engager antibody construct (molecular weight ~55 kDa). Human IgGs are known to cross the placenta, especially in the third trimester. However, given its small size (compared to full IgG), some transfer may occur. No specific clinical data on placental transfer exist. |
| Breastfeeding | It is not known whether blinatumomab is excreted in human milk or absorbed systemically after ingestion. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from blinatumomab, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother. |
| Lactation Rating | L4 (Possibly Hazardous) |
| Teratogenic Risk | Based on its mechanism of action (CD19-directed bispecific T-cell engager) and animal studies, blinatumomab may cause fetal harm. IgG molecules cross the placenta, with increasing transfer in the second and third trimesters. Limited human data exist; however, it is expected to pose a risk of fetal B-cell lymphopenia, immunomodulation, and potential teratogenicity. Use during pregnancy should be avoided unless the benefit clearly outweighs the risk. |
| Fetal Monitoring | For pregnant women receiving blinatumomab, monitor for signs of cytokine release syndrome (CRS), neurological toxicities, and infections. Fetal monitoring should include ultrasonography to assess growth and development, and consider fetal echocardiography if maternal cardiac toxicity occurs. |
| Fertility Effects | No formal human studies on fertility. Animal studies have not been conducted to evaluate effects on fertility. Based on mechanism, potential for impairment of male and female fertility due to effects on immune function and possible gonadal toxicity, but specific data are lacking. |
■ FDA Black Box Warning
Cytokine release syndrome (CRS), which may be life-threatening or fatal; neurological toxicities, including immune effector cell-associated neurotoxicity syndrome (ICANS), which may be severe or fatal.
| Serious Effects |
Known hypersensitivity to blinatumomab or any component of the formulation
| Precautions | Cytokine release syndrome, neurological toxicities (including ICANS), infections, neutropenia and febrile neutropenia, tumor lysis syndrome, leukopenia, increased liver enzymes, pancreatitis, preparation and administration errors, and embryo-fetal toxicity. |
| Food/Dietary | No clinically significant food interactions reported. Grapefruit and grapefruit juice do not affect blinatumomab as it is a monoclonal antibody not metabolized by CYP450 enzymes. No dietary restrictions required. |
| Clinical Pearls | Premedicate with corticosteroids (e.g., dexamethasone 20 mg IV) 1 hour before infusion to reduce the risk of cytokine release syndrome (CRS). Monitor for neurological toxicities, including seizures and encephalopathy, especially during the first 2 doses. Dose adjustments are required for patients with renal impairment (CrCl < 30 mL/min). Blinatumomab is administered as a continuous IV infusion over 28 days per cycle; do not flush the line to prevent bolus administration. |
| Patient Advice | This medication is given as a continuous infusion through a vein over 28 days; you will have a portable infusion pump. · Common side effects include fever, chills, headache, and nausea; these are often manageable with medications. · Seek immediate medical attention if you experience severe headache, confusion, seizures, difficulty speaking, or vision changes (signs of neurological toxicity). · Report any signs of infection such as fever, chills, or sore throat; blinatumomab can lower your white blood cell count. · Do not disconnect, adjust, or stop the infusion pump without consulting your healthcare provider. |
Loading safety data…